Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 4/2013

01-08-2013

ACE2 Activation Confers Endothelial Protection and Attenuates Neointimal Lesions in Prevention of Severe Pulmonary Arterial Hypertension in Rats

Authors: Gang Li, Yinglong Liu, Yaobin Zhu, Aijun Liu, Yulin Xu, Xiaofeng Li, Zhiqiang Li, Junwu Su, Lizhong Sun

Published in: Lung | Issue 4/2013

Login to get access

Abstract

Background

Angiotensin-converting enzyme 2 (ACE2), an ACE homolog, hydrolyzes angiotensin II and opposes its actions, and plays a protective role in the pathogenesis of pulmonary arterial hypertension (PAH). However, the underlying mechanisms involved in the effect of ACE2 on PAH are still uncertain. In this study, we observed the effects of ACE2 activation on endothelial dysfunction and vascular remodeling in the development of severe PAH in rats.

Methods

Severe PAH was induced by monocrotaline injection 1 week following left pneumonectomy, and ACE2 was activated by continuous injection of resorcinolnaphthalein. The PAH-related hemodynamics, pathological changes, and endothelium-dependent vasorelaxation were examined to assess the effects of ACE2 activation. In addition, the changes of the main components of the renin-angiotensin system were identified by ELISA or Western blotting.

Results

Severe PAH was established at 3 weeks and was characterized by high pulmonary arterial pressure (45 mmHg), significant right ventricular hypertrophy, neointimal occlusive lesions, and impaired endothelium-dependent relaxation in pulmonary arteries. Coadministration of resorcinolnaphthalein reduced pulmonary arterial pressure, right ventricular hypertrophy, and neointimal formation and shifted the endothelial-dependent responses toward values measured in normal rats. Theses changes were associated with an increase in ACE2 and angiotensin-(1–7) levels and a decrease in ACE and angiotensin II levels, in addition to a decrease in the ACE/ACE2 ratio and the angiotensin II/angiotensin-(1–7) ratio. The beneficial effects of resorcinolnaphthalein were abolished by A-779.

Conclusions

These findings suggested that ACE2 activation by resorcinolnaphthalein improved endothelial function and suppressed neointimal formation in the prevention of severe PAH by the mechanism of mediating the levels of the components of the renin-angiotensin system.
Literature
1.
Fukumoto Y, Shimokawa H (2011) Recent progress in the management of pulmonary hypertension. Circ J 75(8):1801–1810PubMedCrossRef
2.
Nicod LP (2007) The endothelium and genetics in pulmonary arterial hypertension. Swiss Med Wkly 137:437–442PubMed
3.
Shenoy V, Qi Y, Katovich MJ et al (2011) ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol 11:150–155PubMedCrossRef
4.
5.
Bradford CN, Ely DR, Raizada MK (2010) Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Curr Hypertens Rep 12:212–219PubMedCrossRef
6.
Imai Y, Kuba K, Ohto-Nakanishi T et al (2010) Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 74(3):405–410PubMedCrossRef
7.
Yamazato Y, Ferreira AJ, Hong KH et al (2009) Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 54:365–371PubMedCrossRef
8.
Ferreira AJ, Shenoy V, Yamazato Y et al (2009) Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 179:1048–1054PubMedCrossRef
9.
Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V et al (2008) Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51:1312–1317PubMedCrossRef
10.
Li G, Xu YL, Ling F et al (2012) Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J (Engl) 125(8):1381–1388
11.
Okada K, Tanaka Y, Bernstein M et al (1997) Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 151:1019–1025PubMed
12.
Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811–2821PubMedCrossRef
13.
Hyman AL, Hao Q, Tower A et al (1998) Novel catheterization technique for the in vivo measurement of pulmonary vascular responses in rats. Am J Physiol 274:H1218–H1229PubMed
14.
Nishimura T, Vaszar LT, Faul JL et al (2003) Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108:1640–1645PubMedCrossRef
15.
Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M et al (2005) Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26:1270–1277PubMedCrossRef
16.
Zhong JC, Yu XY, Lin QX et al (2008) Enhanced angiotensin converting enzyme 2 regulates the insulin/Akt signalling pathway by blockade of macrophage migration inhibitory factor expression. Br J Pharmacol 153(1):66–74PubMedCrossRef
17.
Lovren F, Pan Y, Quan A et al (2008) Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 295:H1377–H1384PubMedCrossRef
18.
Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT et al (2007) Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49(1):185–192PubMedCrossRef
19.
Muthalif MM, Benter IF, Uddin MR et al (1998) Signal transduction mechanisms involved in angiotensin-(1–7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther 284(1):388–398PubMed
20.
Zhang C, Zhao YX, Zhang YH et al (2010) Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci USA 107:15886–15891PubMedCrossRef
21.
Rentzsch B, Todiras M, Iliescu R et al (2008) Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 52:967–973PubMedCrossRef
22.
Hacking WJ, VanBavel E, Spaan JA (1996) Shear stress is not sufficient to control growth of vascular networks: a model study. Am J Physiol 270:H364–H375PubMed
23.
Pasterkamp G, Galis ZS, de Kleijn DP (2004) Expansive arterial remodeling: location, location, location. Arterioscler Thromb Vasc Biol 24:650–657PubMedCrossRef
24.
Shenoy V, Ferreira AJ, Qi Y et al (2010) The angiotensin-converting enzyme 2/angiogenesis-(1–7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182:1065–1072PubMedCrossRef
25.
Huang H, Zhang P, Wang Z et al (2011) Activation of endothelin-1 receptor signaling pathways is associated with neointima formation, neoangiogenesis and irreversible pulmonary artery hypertension in patients with congenital heart disease. Circ J 75(6):1463–1471PubMedCrossRef
26.
Curcio A, Torella D, Indolfi C (2011) Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 75(6):1287–1296PubMedCrossRef
27.
Hayashi N, Yamamoto K, Ohishi M et al (2010) The counterregulating role of ACE2 and ACE2-mediated angiotensin 1–7 signaling against angiotensin II stimulation in vascular cells. Hypertens Res 33:1182–1185PubMedCrossRef
28.
Jin XQ, Lu ZQ, Lin X (2011) Effect of ACE2 gene transfection on the proliferation of vascular smooth muscle cells in rats. Zhonghua Yi Xue Za Zhi 91:125–128PubMed
29.
Sampaio WO, Henrique de Castro C et al (2007) Angiotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50:1093–1098PubMedCrossRef
30.
Igase M, Kohara K, Nagai T et al (2008) Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res 31:553–559PubMedCrossRef
31.
Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA et al (2011) Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96(3):287–294PubMedCrossRef
32.
Xie X, Chen J, Wang X et al (2006) Age- and gender-related difference of ACE2 expression in rat lung. Life Sci 78(19):2166–2171PubMedCrossRef
33.
Vickers C, Hales P, Kaushik V et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277:14838–14843PubMedCrossRef
Metadata
Title
ACE2 Activation Confers Endothelial Protection and Attenuates Neointimal Lesions in Prevention of Severe Pulmonary Arterial Hypertension in Rats
Authors
Gang Li
Yinglong Liu
Yaobin Zhu
Aijun Liu
Yulin Xu
Xiaofeng Li
Zhiqiang Li
Junwu Su
Lizhong Sun
Publication date
01-08-2013
Publisher
Springer US
Published in
Lung / Issue 4/2013
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9470-8

Other articles of this Issue 4/2013

Lung 4/2013 Go to the issue

Report

Interstitial Lung Disease in a Child with Antisynthetase Syndrome

OriginalPaper

CT Scanning in the Evaluation of Pulmonary Hypertension

OriginalPaper

Angiotensin-Converting Enzyme (ACE) Gene Polymorphisms are Associated with Idiopathic Pulmonary Fibrosis

OriginalPaper

Angiotensinogen Promoter Polymorphisms Predict Low Diffusing Capacity in U.S. and Spanish IPF Cohorts

OriginalPaper

Exercise Capacity Affects Quality of Life in Patients with Pulmonary Hypertension

OriginalPaper

The Association Between TP53 Arg72Pro Polymorphism and Lung Cancer Susceptibility: Evidence from 30,038 Subjects
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits